Response to Comments: MolDX: Blood Product Molecular Antigen Typing

This document (A58306) is a response-to-comments notice regarding MolDX: Blood Product Molecular Antigen Typing and does not itself define clinical coverage criteria. It notes the LCD identifier L38240 (formerly titled Erythrocyte Molecular Antigen Typing), the public comment period (10/7/2019–11/21/2019), and the LCD notice/effective dates (notice 9/10/2020; effective 10/25/2020). For actionable coverage indications, limitations, documentation requirements, and frequency limits, refer to the full MolDX LCD L38240; manual review of that LCD is required to extract specific policy criteria.